A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.

Lumen Biosciences Brian Finrow breaks down Chinas biotech playbook and explores ways the U.S. can adapt it for its own continued success.

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

Oct 3 (Reuters) - Rocket Pharmaceuticals (RCKT.O), opens new tab said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.

Astromech, a stealth-mode artificial intelligence startup, has successfully raised $30 million according to SEC filings. The company was co-founded by serial entrepreneur Ben Lamm and Harvard ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. IO Biotech ( (IOBT)) has shared an ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged ...